IMVT
Immunovant, Inc.
Key Financials
Operating Income
$-512549
N/A
Net Income
$-505606000
↓ 22.2%
Total Liabilities
$104.4M
↑ 51.8%
Total Assets
$957.0M
↑ 23.3%
Cash & Equivalents
$902.1M
↑ 26.4%
Shareholders' Equity
$852.6M
↑ 20.5%
EPS (Diluted)
$-2.77
↓ 1.5%
Operating Cash Flow
$-407310000.00
↓ 8.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 4 | 7/24/2026 | View on SEC |
| 4 | 7/24/2026 | View on SEC |
| 4 | 7/24/2026 | View on SEC |
| ARS | 7/22/2026 | View on SEC |
| DEFA14A | 7/22/2026 | View on SEC |
| DEF 14A | 7/22/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMVT |
| Company Name | Immunovant, Inc. |
| CIK | 1764013 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | 917-410-3120 |